Who are EFV/TDF/FTC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Atazanavir/ Stavidine / Lamivudine, DOR/3TC/TDF, Lamiduvine (Epivir), Once-daily ABC+3TC, nucleoside reverse transcriptase inhibitors, Dolutegravir / Lamivudine Pill.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/efv-tdf-ftc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

EFV/TDF/FTC — Competitive Intelligence Brief

EFV/TDF/FTC (EFV/TDF/FTC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NNRTI + NtRTI + NRTI). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (NNRTI + NtRTI + NRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

EFV/TDF/FTC (EFV/TDF/FTC) — Juan A. Arnaiz. This is a fixed-dose combination of three antiretroviral agents that work together to inhibit HIV replication through different mechanisms: efavirenz blocks reverse transcriptase, while tenofovir and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
EFV/TDF/FTC TARGET	EFV/TDF/FTC	Juan A. Arnaiz	phase 3	Antiretroviral combination therapy (NNRTI + NtRTI + NRTI)	HIV reverse transcriptase
Atazanavir/ Stavidine / Lamivudine	Atazanavir/ Stavidine / Lamivudine	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
DOR/3TC/TDF	DOR/3TC/TDF	Prism Health North Texas	marketed	Antiretroviral combination therapy (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase
Lamiduvine (Epivir)	Lamiduvine (Epivir)	Catholic University of the Sacred Heart	marketed	Nucleoside Reverse Transcriptase Inhibitor (NRTI)	HIV reverse transcriptase
Once-daily ABC+3TC	Once-daily ABC+3TC	Medical Research Council	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
nucleoside reverse transcriptase inhibitors	nucleoside reverse transcriptase inhibitors	French National Agency for Research on AIDS and Viral Hepatitis	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
Dolutegravir / Lamivudine Pill	Dolutegravir / Lamivudine Pill	Charlotte-Paige Rolle, MD	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NNRTI + NtRTI + NRTI) class)

Juan A. Arnaiz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EFV/TDF/FTC — Competitive Intelligence Brief. https://druglandscape.com/ci/efv-tdf-ftc. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab